ViiV Healthcare, Owned By GSK, Pfizer And Shionogi, Announced The Presentation Of New Real-world Evidence And Implementation Data Showing The Effectiveness, Adherence, And Quality-of-life Improvement Of Apretude (Cabotegravir Long-acting) For HIV Pre-Exposure Prophylaxis
Portfolio Pulse from Benzinga Newsdesk
ViiV Healthcare, owned by GSK, Pfizer, and Shionogi, presented new data on Apretude, a long-acting HIV pre-exposure prophylaxis. The data highlights its effectiveness, adherence, and quality-of-life improvements.
October 16, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK, as a part-owner of ViiV Healthcare, benefits from the positive data on Apretude, which could enhance its market position in HIV prevention.
GSK's involvement in ViiV Healthcare means it stands to gain from the positive reception of Apretude's effectiveness and quality-of-life improvements, potentially increasing its market share in HIV prevention.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, as a part-owner of ViiV Healthcare, could see positive impacts from the new data on Apretude, enhancing its portfolio in HIV prevention.
Pfizer's stake in ViiV Healthcare means it could experience positive effects from the successful data on Apretude, potentially strengthening its position in the HIV prevention market.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70